ECM
PCRX icon

Endurant Capital Management’s Pacira BioSciences PCRX Stock Holding History

Endurant Capital Management’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-10,500
Closed -$359K – 83
2016
Q3 		$359K Hold
10,500
– – 0.13% 81
2016
Q2 		$354K Buy
+10,500
New +$516K 0.12% 78

Other funds holding PCRX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
DCM
Daruma Capital Management New York $879M AUM 2.11% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Endurant Capital Management's PCRX Position: Q4 2016 in Review

Endurant Capital Management sold out of Pacira BioSciences (PCRX) in Q4 2016, closing a stake of 10,500 shares — an estimated $359K sold.

Endurant Capital Management first reported a position in PCRX in Q2 2016 and held it in 2 quarters. The position peaked at $359K in Q3 2016. 182 funds tracked by Wall St. Rank hold PCRX as of Q4 2016.

  • Endurant Capital Management reported no remaining Pacira BioSciences position as of Q4 2016 after selling out during the quarter.
  • Endurant Capital Management sold 10,500 Pacira BioSciences shares in Q4 2016, an estimated $359K.
  • Endurant Capital Management first reported a position in Pacira BioSciences in Q2 2016 and held it in 2 quarters.
  • Endurant Capital Management's Pacira BioSciences position peaked at $359K in Q3 2016.
  • 182 funds tracked by Wall St. Rank held Pacira BioSciences as of Q4 2016.

Based on Endurant Capital Management's 13F filing for Q4 2016, filed 15 Feb 2017.